Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate (AFF RVR): Comparing Calcium Pre-treatment vs Placebo in Prevention of Diltiazem Induced Hypotension

22.135

To compare the relative efficacy for calcium pre-treatment in decreasing incidence of drug induced hypotension after diltiazem administration for treatment of AFF with RVR. Null Hypothesis: There will be no difference between groups in incidence of hypotension after pretreatment with calcium prior to bolus of diltiazem.

2022-11-30

2024-06-01

2026-06-01

Recruiting

Early phase I

92

Inclusion Criteria: * Age \> 18 years or older * Able to provide informed consent * Primary diagnosis AFF with RVR greater than or equal to 120 bpm Exclusion Criteria: * Pregnancy defined as a positive urine HCG * Hemodynamically unstable patients (SBP \<90, MAP \<65) * Stated history of systolic heart failure with reduced ejection fraction (\<40%) or evidence of acute heart failure or reduced EF (peripheral edema, JVD, pulmonary edema) on clinical exam or bedside echo * Patients with left ventricular assist device * Sinus node dysfunction or preexcitation with accessory pathway (known diagnosis of SVT, WPW or sick sinus syndrome. Delta waves or other evidence of accessory pathway on EKG) * 2nd or 3rd degree atrioventricular block * Allergy or sensitivity to any study drugs * Previously enrolled in this trial during a different patient encounter * Non-English speaking

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 92, 'type': 'ESTIMATED'}}

2023-02-02